We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetically Engineered Lactobacilli Cure Diabetes in Rat Model

By LabMedica International staff writers
Posted on 09 Feb 2015
Print article
Image: Micrograph showing a rat cell re-programmed to express HNF-6 (red) and insulin (green). The nucleus is stained blue (Photo courtesy of Cornell University).
Image: Micrograph showing a rat cell re-programmed to express HNF-6 (red) and insulin (green). The nucleus is stained blue (Photo courtesy of Cornell University).
A novel concept for treating diabetes was demonstrated by feeding diabetic rats a diet containing human lactobacilli that had been genetically engineered to secrete the protein glucagon-like peptide-1 GLP-1(1–37), which induced significant long-term increases in insulin levels.

The inactive full-length form of GLP-1(1–37) has been shown previously to stimulate conversion of both rat and human intestinal epithelial cells into insulin-secreting cells. GLP-1 is normally induced by feeding and stimulates insulin secretion in response to glucose. It is a member of the incretin group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta cells of the islets of Langerhans after eating, even before blood glucose levels become elevated. They also slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. Incretins also inhibit glucagon release from the alpha cells of the Islets of Langerhans.

Investigators at Cornell University (Ithaca, NY, USA) examined whether oral administration of human commensal bacteria engineered to secrete GLP-1(1–37) could modulate glucose metabolism in a rat model of diabetes by reprogramming intestinal cells into glucose-responsive insulin-secreting cells. Toward this end they genetically engineered a strain of Lactobacillus to secrete GPL-1(1-37). The bacteria were fed to diabetic rats for 90 days.

Results published in the January 27, 2015, online edition of the journal Diabetes revealed that the rats receiving the engineered bacteria demonstrated a reduction of up to 30% in blood glucose levels. These rats developed insulin-producing cells within the upper intestine in numbers sufficient to replace approximately 25%–33% of the insulin capacity of nondiabetic healthy rats. Intestinal tissues in rats with reprogrammed cells expressed the pancreatic beta-cell markers MafA (mast cell function-associated antigen), PDX-1 (insulin promoter factor 1), and FoxA2 (forkhead box protein A2). HNF-6 (hepatocyte nuclear factor-6) expression was observed only in crypt epithelia expressing insulin and not in epithelia located higher on the villous axis.

Staining for other cell markers in rats treated with GLP-1(1–37)-secreting bacteria suggested that normal cells were not affected by the close physical proximity of reprogrammed cells.

“The amount of time to reduce glucose levels following a meal is the same as in a normal rat, and it is matched to the amount of glucose in the blood, just as it would be with a normal-functioning pancreas,” said senior author Dr. John D. March, professor of biological and environmental engineering at Cornell University. “It is moving the center of glucose control from the pancreas to the upper intestine.”

The GLP-1 technology has been licensed by BioPancreate, a wholly-owned subsidiary of the biopharmaceutical company Cortendo AB (Radnor, PA, USA), which will be attempting to adapt it for use as therapy for human diabetes.

Related Links:
Cornell University
Cortendo AB 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.